BioPep’s Publication Outlines Promising New Treatment Options for Restoring Damaged Cartilage in Osteoarthritis, which Affects Millions Worldwide
Cartilage diseases include many joint disorders, joint injuries and cartilage tumors that involve degenerative changes in joints. Joint degenerative disorders are becoming an increasingly burden as their incidence is rising worldwide. As we age, joint damage is even more likely to continue to occur.
Osteoarthritis (OA) is the most common form of chronic cartilage diseases, affecting an estimated 250 million people worldwide. In fact, OA is assumed to be the fourth leading cause of disability in the world in 2020. OA affects the knees, hips, hands, feet, and spine; however, the knee is the most frequently affected site, followed by the hand and hip.
A number of risk factors such as female sex, age, obesity, genetic factors, and oxidative stress increase the chances of developing OA. It is growing more prevalent today because of the combined factors of aging, obesity and the increasing numbers of damaged joints.
BioPep’s scientists have recently published a paper in the prestigious Stem Cell & Regenartive Medicine Journal. The paper reviewed the promising evidence for stem cell use in treating cartilage diseases such as osteoarthritis.
The challenges associated with treating cartilage diseases include poor understanding of the disease process, delayed diagnosis and difficulty of drugs being able to reach the damaged cartilage. The main goals of OA treatment are pain relief and slowing down or halting the progression of OA. Surgical correction is the next step to treat OA.
Currently, drug treatment options for osteoarthritis are limited to anti-inflammatory medicines and biologic therapies, which give relief but don’t fix the condition itself. These treatments treat the inflammation, but not the destructive underlying process in the joints. Biological therapies are not intended for long term use and steroid usage has a variety of unwanted side effects and can not be used long term. The widely used pharmacological treatments for OA have shown limited benefits, and further studies are required.
There is an unmet need to safely and effectively treat or delay joint damage in joint disease sufferers. At BioPep, we believe that better health is achievable through safe, scientifically tested organopeptides, which can help tissue rejuvenation in joints that are worn and damaged by aging or disease.
Regenerative treatments are intended to repair and replace the injured cells and tissues with new ones. Existing regenerative approaches however, are currently limited. Using hyaluronic acid can stimulate the body’s production of natural hyaluronic acid and in doing so suppress cartilage destruction and promote regeneration. In some studies, platelet-rich plasma was used in tissue repair and showed pain alleviation and improvements in function that were sustained for 6 months.
Promising new bioregenerative technologies offer exciting therapeutic options for OA patients. Stem cells have been proposed as regenerative cell therapy for OA, due to their potential for self-renewal and differentiation into cartilage and immune modulating capabilities. Stem cell-based therapy is gaining interest worldwide because of its potential in the regeneration of new cartilage and strong immunoregulatory capacity.
Mesenchymal stem cells are stem cells with a high capability of proliferating and differentiating into other cell types and have been applied in several studies. Positive results in preclinical and clinical trials have demonstrated that mesenchymal and tissue-specific stem cell therapies are a promising strategy in the treatment of OA.
A number of clinical trials have demonstrated the potential efficacy of stem cells derived from bone marrow, adipose tissue, and umbilical cord blood in the treatment of OA. A systematic review of 61 studies of OA and stem cell therapy in humans done by Jevotovsky et al. (2018) concluded that stem cell therapy has a positive effect on OA patients, but that further research is required to progress the field.
Cell therapy, especially cartilage stem cell-based therapy, is becoming an encouraging approach to regenerative medicine in the treatment of OA. The promising effects of cartilage stem cell therapy indicate that it can possibly achieve better regenerative efficacy for degenerative joint disorders when used in combination with other treatments.
The study of OA, particularly the use of stem cell therapy in joint disease research, has attracted considerable attention. Studies have been carried out on the function and characteristics of certain tissue-specific stem cells and their application in cartilage regeneration to treat OA. According to reports from basic research and clinical trials, stem cell treatment is safe and effective to treat osteoarthritis.
BioPep is an R&D biotech company, a subsidiary of European Wellness Biomedical Group (EW) that is focused on the scientific study of existing products manufactured by European Wellness Biomedical Group, as well as developing innovative new products in collaboration with a Colorado-based US FDA registered facility. At BioPep, we believe that better health is achievable through safe, scientifically tested organopeptides and other bioregenerative technologies. Our organopeptides, which are Nano Organo Peptides or Mito Organelles (NOPs and MOs), are manufactured by European Wellness Biomedical Group at the EW facility in Europe who are committed to ensuring that all organopeptide products are pathogen-free and safe. These organopeptides are being used rejuvenate and improve health.
We partner with top-tier research institutions, universities and manufacturing facilities to provide data on the effectiveness of organ-specific peptides’ ability to rejuvenate and heal. This study outlines the promising evidence for stem cells treatments in OA and could also pave the way for alleviating the pain and suffering of millions of cartilage disease sufferers worldwide.
Yuriy Nalapko, Dmytro Klokol, Jonathan R.T. Lakey, et al. Novel Bioregenerative Options for Chondrocyte Restoration in Osteoarthritis. Stem Cells Regen Med. 2022; 6(1): 1-8.